Stock Events

Stock Events

Clarity Pharmaceuticals 

A$3.13
31
-A$0.09-2.8% Friday 06:12

Statistics

Day High
3.23
Day Low
3.13
52W High
5.7
52W Low
1.62
Volume
9,793,047
Avg. Volume
-
Mkt Cap
1.16B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

25FebExpected
Q2 2022
Q4 2023
Q2 2024
Q3 2024
Q4 2024
Q2 2025
Q4 2025
-0.14
-0.1
-0.05
0
Expected EPS
-0.07741502092872994
Actual EPS
-0.1433958620108436

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-128.59MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CU6.AU. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Novartis
NVS
Mkt Cap297.35B
Novartis is a global healthcare company that operates in the pharmaceuticals sector, directly competing with Clarity Pharmaceuticals in the development and marketing of therapeutic products.
Pfizer
PFE
Mkt Cap153.13B
Pfizer is a large pharmaceutical company with a broad range of products that compete in various therapeutic areas covered by Clarity Pharmaceuticals.
Merck
MRK
Mkt Cap300.2B
Merck & Co., Inc. is a global healthcare company that develops medicines, vaccines, biologic therapies, and animal health products, competing across several of Clarity Pharmaceuticals' focus areas.
Johnson & Johnson
JNJ
Mkt Cap574.66B
Johnson & Johnson is a diversified healthcare giant that competes with Clarity Pharmaceuticals through its pharmaceutical division, particularly in oncology and immunology.
Abbvie
ABBV
Mkt Cap367.8B
AbbVie operates in the pharmaceutical industry, focusing on immunology, oncology, and virology, which overlaps with Clarity Pharmaceuticals' therapeutic areas.
AMGEN
AMGN
Mkt Cap189.22B
Amgen is a biotechnology company focused on cardiovascular disease, oncology, bone health, neuroscience, nephrology, and inflammation, competing with Clarity Pharmaceuticals in several key areas.
Bristol-Myers Squibb
BMY
Mkt Cap119.69B
Bristol Myers Squibb is a global biopharmaceutical company with a focus on discovering, developing, and delivering innovative medicines that compete with Clarity Pharmaceuticals' product lines.
Gilead Sciences
GILD
Mkt Cap172.51B
Gilead Sciences is a biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics in areas of unmet medical need, directly competing with Clarity Pharmaceuticals.
Astrazeneca
AZN
Mkt Cap316.3B
AstraZeneca is a global, science-led biopharmaceutical business that focuses on the discovery, development, and commercialization of prescription medicines, including those in areas competing with Clarity Pharmaceuticals.
Roche
RHHBY
Mkt Cap322.3B
Roche Holding AG is a leader in research-focused healthcare with strengths in pharmaceuticals and diagnostics, competing in therapeutic areas relevant to Clarity Pharmaceuticals.

About

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceuticals products for oncology in Australia and the United States. The company's lead product is SAR-bisPSMA, a theranostic radiopharmaceutical for the treatment of Prostate Specific Membrane Antigen (PSMA) cancer. It also develops SAR-Bombesin, a pan cancer theranostic radiopharmaceutical to treat prostate, breast, ovarian, urinary, small cell lung cancer, as well as glioblastoma and gastrointestinal stromal tumours; and SARTATE, a theranostic radiopharmaceutical for the treatment of somatostatin receptor 2 (SSTR2) cancer. The company was incorporated in 2010 and is based in Sydney, Australia.
Show more...
CEO
Dr. Alan John Taylor Ph.D.
Employees
88
Country
Australia
ISIN
AU0000165375

Listings

F
DE
1F4.F
AU
AU
CU6.AU
OTC Link
US
CLRPF

0 Comments

Share your thoughts

FAQ

What is Clarity Pharmaceuticals stock price today?▼
The current price of CU6.AU is A$3.13 AUD — it has decreased by -2.8% in the past 24 hours. Watch Clarity Pharmaceuticals stock price performance more closely on the chart.
What is Clarity Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Clarity Pharmaceuticals stocks are traded under the ticker CU6.AU.
Is Clarity Pharmaceuticals stock price growing?▼
CU6.AU stock has fallen by -1.57% compared to the previous week, the month change is a -9.8% fall, over the last year Clarity Pharmaceuticals has showed a +64.74% increase.
What is Clarity Pharmaceuticals market cap?▼
Today Clarity Pharmaceuticals has the market capitalization of 1.16B
When is the next Clarity Pharmaceuticals earnings date?▼
Clarity Pharmaceuticals is going to release the next earnings report on August 26, 2026.
What were Clarity Pharmaceuticals earnings last quarter?▼
CU6.AU earnings for the last quarter are -0.14 AUD per share, whereas the estimation was -0.08 AUD resulting in a -85.23% surprise. The estimated earnings for the next quarter are N/A AUD per share.
What is Clarity Pharmaceuticals revenue for the last year?▼
Clarity Pharmaceuticals revenue for the last year amounts to 0 AUD.
What is Clarity Pharmaceuticals net income for the last year?▼
CU6.AU net income for the last year is -128.59M AUD.
How many employees does Clarity Pharmaceuticals have?▼
As of April 19, 2026, the company has 88 employees.
In which sector is Clarity Pharmaceuticals located?▼
Clarity Pharmaceuticals operates in the Health & Wellness sector.
When did Clarity Pharmaceuticals complete a stock split?▼
Clarity Pharmaceuticals has not had any recent stock splits.
Where is Clarity Pharmaceuticals headquartered?▼
Clarity Pharmaceuticals is headquartered in Sydney, Australia.